N4 Pharma PLC Technology Transfer and Manufacturing Contract (5453X)
01 September 2020 - 8:00AM
UK Regulatory
TIDMN4P
RNS Number : 5453X
N4 Pharma PLC
01 September 2020
1 September 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Technology Transfer and Manufacturing Contract
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing, a novel delivery system for cancer treatments and
vaccines, announces that it has appointed the API and Nanomedicines
business unit of Ardena ('Ardena') as its contract development and
manufacturing organisation ('CDMO') partner for the technology
transfer and upscaling manufacture of Nuvec(R).
The contract is divided into three stages:
1. Establishing an understanding of the current manufacture
process, scale-up and analysis of the transfer of technology;
2. Process optimisation and scale-up resulting in the
manufacture and analysis of a non-GMP 50g batch of Nuvec(R);
3. Manufacture, testing and product certification of Nuvec(R) for GMP status
The manufacture will initially be for the fundamental "naked"
Nuvec(R) silica nanoparticles albeit Ardena has the ability to
produce functionalised particles as may be required by the Company
or any collaborators from time to time.
Ardena is a CDMO based in the Netherlands with substance and
drug product manufacturing capability and is experienced in the
manufacture of nanoparticles (liposomes, PLGA micro and
nanospheres, silica nanoparticle) which is of particular relevance
for Nuvec(R). Ardena also has a GMP manufacturing, analytical and
product release capability.
Nigel Theobald, Chief Executive Officer, commented: "We are
delighted to be working with Ardena as our tech transfer and
manufacturing partner. As we look to continue the advancement of
Nuvec(R) and its applications it is increasingly important that we
have access to a consistent Nuvec(R) product across our studies
together with the potential to move to GMP certification as and
when required and Ardena can provide this."
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTEAPPFDAFEEFA
(END) Dow Jones Newswires
September 01, 2020 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024